Antibodiesinc/BAF53a/75-330/1 Ea
商品编号：
75-330
市场价：
¥0.00
美元价：
0.00
产品分类：
重组抗体
公司分类：
Recombinant_antibodies
联系Q Q：
3392242852
电话号码：
4000-520-616
电子邮箱：
info@ebiomall.com
商品介绍
Immunogen:
Fusion protein amino acids 43-119 (MVVERDDGSTLMEIDGDKGKQGGPTYYIDTNALRVPRENME AISPLKNGMVEDWDSFQAILDHTYKMHVKSEASLHP, actin subdomain 2) of human BAF53a (also known as 53 kDa BRG1-associated factor A, BRG1-associated factor 53A, Actin-like protein 6A, ArpNbeta, ACTL6A, INO80 complex subunit K and INO80K, accession number O96019)
Mouse: 96% identity (74/77 amino acids identical)
Rat: 94% identity (73/77 amino acids identical)
>50% identity with BAF53a
Fusion protein amino acids 43-119 (MVVERDDGSTLMEIDGDKGKQGGPTYYIDTNALRVPRENME AISPLKNGMVEDWDSFQAILDHTYKMHVKSEASLHP, actin subdomain 2) of human BAF53a (also known as 53 kDa BRG1-associated factor A, BRG1-associated factor 53A, Actin-like protein 6A, ArpNbeta, ACTL6A, INO80 complex subunit K and INO80K, accession number O96019)
Mouse: 96% identity (74/77 amino acids identical)
Rat: 94% identity (73/77 amino acids identical)
>50% identity with BAF53a
Specifications:
Target |
|
BAF53a |
|
|
||
Classification |
|
Other |
|
|
||
Applications |
|
Immunoblot (IB) Immunocytochemistry (ICC) |
|
|
||
Clone |
|
N336B/83 |
|
|
||
IgG Isotype |
|
IgG2b |
|
|
||
Species Reactivity |
|
Human (H) Mouse (M) Rat (R) |
|
|
||
Validation |
|
T |
|
|
||
Type |
|
Purified |
|
|
||
Format |
|
100 ul |
|
|
||
Cross Reactivity |
|
Does not cross-react with BAF53b |
|
|
||
Expected Banding Pattern |
|
53 kDa |
|
|
||
Host |
|
Mouse (M) |
|
|
||
Label |
|
Unlabeled |
|
|
||
Antibody Type |
|
Monoclonal |
|
|
||
Commercial Price |
|
450 |
|
|
||
Non-Profit Price |
|
200 |
|
|
||
Distributor Price |
|
Per Contract(QUOTE) |
|
|
||
ABID |
|
RRID:AB_2315809 |
|
|
||
品牌介绍
当抗体公司（Antibodies Incorporated）在1962年开业时，与抗体相关的研究才刚刚开始。创始人Jim Hillman拥有博士学位。从药理学明尼苏达大学，来到加州大学戴维斯分校在免疫化学完整的博士后工作，在工作期间，他学习了加州理工学院（加州理工学院）根据丹·坎贝尔，领域的先驱。吉姆带来了他的妻子，公司的共同创始人卡罗尔（Carol）和两个孩子，以及使用基于抗体的化学疗法寻找治疗癌症的能量和想法。具体地说，吉姆认为，如果他能够识别并分离出可能具有抗原性的肿瘤部位（一个焦点是淋巴肉瘤），则可能有可能进行有效的基于抗体的治疗。吉姆寻找这种治疗方法的梦想推动了他的工作多年。
